Hikma Pharmaceuticals Plc Result of AGM (7108F)

TIDMHIK

RNS Number : 7108F

Hikma Pharmaceuticals Plc

19 May 2017

Hikma Pharmaceuticals PLC

Voting Results of 2017 Annual General Meeting

LONDON, 19 May 2017 - Hikma Pharmaceuticals PLC (the "Company") announces its Annual General Meeting ("AGM"), held at Sofitel St James, 6 Waterloo Place, London SW1Y 4AN on 19 May 2017 commenced at 10:00 am today. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 19 were passed as ordinary resolutions and Resolutions 20 to 23 were passed as special resolutions.

As previously announced, Mr. Michael Ashton retired from the Board at the close of the AGM.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the UK Listing Authority for publication through the Listing Authority's Document Viewing Facility.

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 7 April 2017) is set out below. The number of Ordinary Shares in issue on 19 May 2017 was 240,380,475.

 
        Resolution             Votes         %        Votes        %      Withheld    Total Cast 
                                For                   Against 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 1. To receive 
  the 2016 report 
  and accounts              197,423,759   99.84%     319,920     0.16%      6,643     197,750,322 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 2. To approve 
  a final dividend 
  of 22 cents 
  per share                 197,743,879   100.00%       0        0.00%      6,443     197,750,322 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 3. To re-appoint 
  PricewaterhouseCoopers 
  LLP as auditors           197,741,251   100.00%      905       0.00%      8,166     197,750,322 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 4.To authorise 
  the Audit Committee 
  to determine 
  the auditors' 
  remuneration              197,688,953   99.97%      53,203     0.03%      8,166     197,750,322 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 5. To elect 
  Nina Henderson 
  as a director             197,534,627   99.89%     208,786     0.11%      6,854     197,750,267 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 6. To re-elect 
  Said Darwazah 
  as a director             193,519,353   98.05%    3,848,526    1.95%     382,442    197,750,321 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 7. To re-elect 
  Mazen Darwazah 
  as a director             195,813,592   99.21%    1,551,895    0.79%     384,835    197,750,322 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 8. To re-elect 
  Robert Pickering 
  as a director             197,076,319   99.66%     667,559     0.34%      6,443     197,750,321 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 9.To re-elect 
  Ali Al-Husry 
  as a director             196,769,085   99.57%     857,947     0.43%     123,290    197,750,322 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 10. To re-elect 
  Dr. Ronald 
  Goode as a 
  director                  195,703,815   98.97%    2,039,923    1.03%      6,584     197,750,322 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 11. To re-elect 
  Patrick Butler 
  as a director             197,506,890   99.88%     236,848     0.12%      6,584     197,750,322 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 12. To re-elect 
  Dr. Jochen 
  Gann as a director        196,795,912   99.58%     830,979     0.42%     123,431    197,750,322 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 13. To re-elect 
  John Castellani 
  as a director             197,586,602   99.92%     157,277     0.08%      6,443     197,750,322 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 14. To re-elect 
  Dr. Pamela 
  Kirby as a 
  director                  195,665,777   98.96%    2,053,602    1.04%      6,468     197,725,847 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 15. To approve 
  the directors' 
  remuneration 
  policy                    169,053,856   86.39%    26,622,257   13.61%   2,074,207   197,750,320 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 16. To approve 
  the remuneration 
  report for 
  the year ended 
  31 December 
  2016                      193,651,599   97.93%    4,091,754    2.07%      6,968     197,750,321 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 17. To approve 
  the extension 
  of the effective 
  period of the 
  Executive Incentive 
  Plan                      170,276,525   86.12%    27,450,966   13.88%    22,830     197,750,321 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 18. To approve 
  the increase 
  of the aggregate 
  directors' 
  fee limit                 197,640,307   99.98%      45,091     0.02%     64,924     197,750,322 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 19. Authority 
  to allot shares           170,146,304   86.21%    27,221,034   13.79%    382,984    197,750,322 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 20. To dis-apply 
  pre-emption 
  rights for 
  general purposes          196,872,145   99.56%     869,023     0.44%      9,154     197,750,322 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 21. To dis-apply 
  pre-emption 
  rights for 
  an acquisition 
  or other capital 
  investment                173,591,716   87.79%    24,149,939   12.21%     8,666     197,750,321 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 22. To authorise 
  the Company 
  to purchase 
  its own shares            197,014,413   99.66%     676,265     0.34%     59,643     197,750,321 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 23. To authorise 
  the Company 
  to hold general 
  meetings on 
  no less than 
  14 clear days' 
  notice                    187,053,655   94.82%    10,213,802   5.18%     482,864    197,750,321 
-------------------------  ------------  --------  -----------  -------  ----------  ------------ 
 

Declaration of final dividend

The dividend of 22 cents per share will be paid on 25 May 2017 to shareholders on the register on 7 April 2017. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.2898 to GBP1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa 1JD to $1.41.

- ENDS -

Enquiries:

 
 Hikma Pharmaceuticals PLC 
 Peter Speirs 
  Company Secretary                [phone] 
 Susan Ringdal 
  VP for Investor Relations and 
  Strategy                         [phone] 
 

About Hikma

Hikma Pharmaceuticals PLC is a fast-growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Injectables", "Branded" and "Generics", based principally in the United States, the Middle East and North Africa ("MENA") and Europe. In 2016, Hikma achieved revenue of $1,950 million and profit attributable to shareholders of $155 million. In the United States, Hikma operates through its wholly owned subsidiary, West-Ward Pharmaceuticals Corp., with operations based in New Jersey, Ohio and Tennessee. For more information visit www.hikma.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGSFEFDUFWSELI

(END) Dow Jones Newswires

May 19, 2017 09:44 ET (13:44 GMT)